Monoclonal Antibodies
Improving Quality of Life
Lead Candidate
A New Frontier in Bacterial Infections, Inflammatory, Metabolic & Infectious Disease
Longhorn Vaccines and Diagnostics is building a new class of anti-bacterial immunotherapies designed to target the conserved cell-wall structures that sit upstream of infection, sepsis, and chronic inflammation. Rather than chasing individual pathogens or downstream cytokines, Longhorn’s platform focuses on bacterial pattern-associated molecular patterns, including peptidoglycan and lipoteichoic acid, that are shared across clinically important organisms and capable of driving inflammatory pathology even after bacterial killing begins.
The lead program, LHNVD-501, is a humanized, extended-half-life monoclonal antibody derived from Longhorn’s anti-peptidoglycan work. It is designed to bind conserved peptidoglycan structures across Gram-positive, Gram-negative, and mycobacterial organisms, with the goal of both promoting immune clearance of bacteria (Opsonization data on multiple staphylococci, E. coli, P. aeruginosa, and MTB) and neutralizing circulating peptidoglycan fragments that activate innate immune pathways. This creates a dual opportunity: adjunctive therapy for serious bacterial infection and sepsis, and a broader strategy for reducing persistent bacterial-component-driven inflammation.
Longhorn’s second major asset, LHNVD-502, extends a clinically validated anti-bacterial lineage originally developed by Longhorn leadership as pagibaximab. Now modified as a modern humanized, extended-half-life antibody, LHNVD-502 binds a conserved Gram-positive cell-wall inflammatory trigger with prior human safety and pharmacology precedent. In combination, LHNVD-501 and LHNVD-502 are designed to address the biology of bacterial sepsis more completely than either target alone, reflecting evidence that peptidoglycan and lipoteichoic acid can act together to amplify shock, cytokine release, nitric-oxide signaling, and multi-organ dysfunction.
The antibodies are intended to complement, not replace, standard-of-care antimicrobials: antibiotics expose and release bacterial cell-wall antigens, while antibodies can help opsonize bacteria, clear debris, and dampen the inflammatory consequences of bacterial breakdown. That combination could be especially valuable in high-risk settings such as ICU admission, neonatal sepsis prevention, antimicrobial-resistant infections, and other conditions where bacterial products continue to drive pathology.
Longhorn’s vision is to turn conserved bacterial cell-wall targets into a scalable therapeutic platform. By pairing broad-spectrum anti-peptidoglycan coverage with anti-lipoteichoic acid lineage validation, the company is advancing a biologic approach that could reduce infection severity, improve immune clearance, and interrupt the upstream inflammatory signals that underlie sepsis and bacterial-component-associated disease. The result is a platform with near-term infectious-disease applications and long-term potential across inflammation, aging, and chronic disease biology.
LHNVD-501 Recently Presented Data
ANTI-INFLUENZA MONOCLONAL ANTIBODY PROGRAM
A broadly reactive monoclonal antibody cocktail targeting influenza's most conserved epitopes
LHNVD-601, LHNVD-602, and LHNVD-603 are neutralizing monoclonal antibodies raised against highly conserved hemagglutinin, neuraminidase, and matrix targets — engineered to remain effective as influenza strains evolve.
Research
-
Opsonic Monoclonal Antibodies Directed Against MTB Enhance Blood Clearance in a Quantitative qPCR Mouse Model
-
Antibody Mediated Killing of Mycobacteria by Macrophage Cells Correlates with In Vivo Blood Clearance of Mycobacterium Tuberculosis
-
A novel monoclonal antibody enhances phagocytosis and killing of Mycobacterium Tuberculosis in macrophage cells
-
Conserved Influenza Hemagglutinin, Neuraminidase and Matrix Peptides Adjuvanted with ALFQ Induce Broadly Neutralizing Antibodies